Evidence map›Paper›PMID 22927523›Full record

ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2012

Aspirin use and the risk of prostate cancer mortality in men treated with prostatectomy or radiotherapy.

Kevin S Choe, Janet E Cowan, June M Chan, Peter R Carroll, Anthony V D'Amico, Stanley L Liauw

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
55citing papers in PubMed, 7 pooled it
13.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

55 citing papers in PubMed, 7 syntheses or guidelines pooled it, 109 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Trial
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Anesthesia and Oncology: Friend or Foe?Frontiers in oncology · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Kevin S ChoeUniversity of Texas Southwestern Medical Center, Dallas, TX, USA.
Janet E Cowan
June M Chan
Peter R Carroll
Anthony V D'Amico
Stanley L Liauw
St. Mary's Medical Center · US

Funding

PSA SCREENING AND US PROSTATE CANCER TRENDSU01CA088160 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI ETZIONI, RUTH D · 2000 to 2009
$2.7M
Effectiveness of Early Stage Prostate Cancer TreatmentRC1CA146596 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI CARROLL, PETER R, SANDA, MARTIN G. · 2009 to 2010
$996k
NCI NIH HHS 1U01CA88160NCI NIH HHS 5RC1CA146596NCI NIH HHS RC1 CA146596NCI NIH HHS U01 CA088160
6 · The paper itself

Abstract

purposeExperimental evidence suggests that anticoagulants (ACs) may inhibit cancer growth and metastasis, but clinical data have been limited. We investigated whether use of ACs was associated with the risk of death from prostate cancer. PATIENTS AND

methodsThis study comprised 5,955 men in the Cancer of the Prostate Strategic Urologic Research Endeavor database with localized adenocarcinoma of the prostate treated with radical prostatectomy (RP) or radiotherapy (RT). Of them, 2,175 (37%) were receiving ACs (warfarin, clopidogrel, enoxaparin, and/or aspirin). The risk of prostate cancer-specific mortality (PCSM) was compared between the AC and non-AC groups.

resultsAfter a median follow-up of 70 months, risk of PCSM was significantly lower in the AC group compared with the non-AC group (3% v 8% at 10 years; P < .01). The risks of disease recurrence and bone metastasis were also significantly lower. In a subgroup analysis by clinical risk category, the reduction in PCSM was most prominent in patients with high-risk disease (4% v 19% at 10 years; P < .01). The benefit from AC was present across treatment modalities (RT or RP). Analysis by type of AC medication suggested that the PCSM reduction was primarily associated with aspirin. Multivariable analysis indicated that aspirin use was independently associated with a lower risk of PCSM (adjusted hazard ratio, 0.43; 95% CI, 0.21 to 0.87; P = .02).

conclusionAC therapy, particularly aspirin, was associated with a reduced risk of PCSM in men treated with RT or RP for prostate cancer. The association was most prominent in patients with high-risk disease.

Indexed as

ChemopreventionProstatectomyAdenocarcinomaAdultAgedAged, 80 and overAnticoagulantsAspirinClopidogrelEnoxaparinHumansMaleMiddle AgedProstatic NeoplasmsRiskTiclopidineAnticoagulantsAspirinClopidogrelEnoxaparinTiclopidineWarfarin

Identifiers

PMID22927523
PMCPMC3454771
OpenAlexW2128271389

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.